Payment overview · 2025
General Payments
$61.16
4 reported records · 4 companies
Healthcare provider profile · identity verified
Robert D Grimshaw, DO
Allopathic & Osteopathic Physicians|Family Medicine · BIRCH RUN, MI · NPI 1174562912
Verified facts
What the public records show
CMS Open Payments records show Robert D Grimshaw, DO received $61.16 in general payments during 2025 across 4 reported records.
Exact Sciences Corporation accounted for 30.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.53 | 30.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.48 | 23.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.48 | 23.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.67 | 22.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $61.16 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.53 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.67 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 414 | 128 |
| Atorvastatin Calcium | Atorvastatin Calcium | 388 | 109 |
| Metformin Hcl | Metformin Hcl | 366 | 99 |
| Lisinopril | Lisinopril | 361 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 315 | 87 |
| Omeprazole | Omeprazole | 277 | 80 |
| Losartan Potassium | Losartan Potassium | 274 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 271 | 66 |
| Jardiance | Empagliflozin | 232 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 198 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 189 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 181 | 49 |
| Simvastatin | Simvastatin | 146 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 143 | 43 |
| Furosemide | Furosemide | 135 | 40 |
| Eliquis | Apixaban | 134 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 129 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 37 |
| Glipizide Er | Glipizide | 117 | 33 |
| Trulicity | Dulaglutide | 114 | 20 |
| Potassium Chloride | Potassium Chloride | 104 | 30 |
| Gabapentin | Gabapentin | 101 | 27 |
| Allopurinol | Allopurinol | 97 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 89 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 84 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 77 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 25 |
| Metformin Hcl Er | Metformin Hcl | 75 | 21 |
| Carvedilol | Carvedilol | 74 | 23 |
| Prednisone | Prednisone | 74 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 18 |
| Mounjaro | Tirzepatide | 62 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 15 |
| Montelukast Sodium | Montelukast Sodium | 51 | 13 |
| Tramadol Hcl | Tramadol Hcl | 51 | 11 |
| Ezetimibe | Ezetimibe | 48 | 18 |
| Novolog Flexpen | Insulin Aspart | 48 | 15 |
| Famotidine | Famotidine | 45 | 17 |
| Trazodone Hcl | Trazodone Hcl | 45 | 13 |
| Alendronate Sodium | Alendronate Sodium | 43 | 19 |
| Nystatin | Nystatin | 43 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 12 |
| Donepezil Hcl | Donepezil Hcl | 42 | 12 |
| Glipizide | Glipizide | 41 | 15 |
| Sertraline Hcl | Sertraline Hcl | 41 | 13 |
| Atenolol | Atenolol | 39 | 13 |
| Baclofen | Baclofen | 38 | 19 |
| Ibuprofen | Ibuprofen | 36 | 11 |
| Meloxicam | Meloxicam | 36 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | 11 |
| Lovastatin | Lovastatin | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 13 |
| Glimepiride | Glimepiride | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | 11 |
| Invokana | Canagliflozin | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 13 |
| Acyclovir | Acyclovir | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 14 |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Azithromycin | Azithromycin | 17 | 16 |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $61.16 · 4 records | Exact Sciences Corporation | Dexcom G6 Transmitter, FREESTYLE LIBRE 3, Ozempic, Rybelsus, The Cologuard Plus Collection Kit | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error